In today's ACT Brief, we examine why eClinical platforms must prioritize user workflows over data flow, how digitizing sample tracking prevents integrity failures in transit, and the FDA's ...

ONCOMATRYX, a Spanish biopharmaceutical company developing Quantum ADCs against the tumor microenvironment, has successfully raised $67 million to foster the clinical development of novel candidates.

Company completed treatment in four additional participate at its Israel clinical siteVancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- ...

DermTech 2.0 ("DermTech LLC" or "The Company"), a leader in precision dermatology enabled by DermTech's proprietary non-invasive Smart Sticker(R) skin sample collection platform, announced today the ...

BioVersys strengthens its Ansamycin Chemistry platform and research on tackling difficult-to-treat non-tuberculous mycobacteria (NTM) diseases. BioVersys joins forces with Hackensack Meridian Health ...

The trial will compare the safety and efficacy of equecabtagene autoleucel versus standard therapies in r/r MM patients.

Results from the OASIS 4 clinical trial show that a new drug, elinzanetant, relieved hot flashes and night sweats that can ...

The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship ...

The MU Research Reactor has partnered with ABK Biomedical to conduct an in-person clinical trial targeted at finding a treatment for liver tumors.

Novel agent outperforms placebo in phase II trial, but is it enough?

An executive order upended an NIH policy requiring researchers to account for both sexes in preclinical animal studies.

Researchers at the University of Bayreuth have, for the first time, deciphered key steps in the biosynthetic mechanism of the ...